| Abstrakt: |
Background: Leukemia is a group of cancers that usually begin in the bone marrow and results in a large number of abnormal white blood cells. Chronic Lymphocytic Leukemia is the most prevalent leukemia in Western countries, with an estimated incidence rate of less than 1 to 5.5 per 100 000 people, and average age at diagnosis of 64 to 72 years. It is more common in men among Chronic Lymphocytic Leukemia patients in Ethiopia's hospitals at Felege Hiwot Referal Hospital. Methods: A retrospective cohort research design was employed to acquire critical information from patients' medical records in order to achieve the study's purpose. The study comprised the medical records of 312 Chronic Lymphocytic Leukemia who were followed from January 1, 2018 to December 31, 2020. A Cox proportional hazard model was used to determine the risk factors for time to death in Chronic Lymphocytic Leukemia patients. Results: Accordingly the Cox proportional hazard model, age (Hazard Ratio = 11.36; P <.001), sex of male (Hazard Ratio = 1.04; P =.004), married status (Hazard Ratio = 0.03; P =.003), medium stages of Chronic Lymphocytic Leukemia (Hazard Ratio = 1.29; P =.024), high stages of Chronic Lymphocytic Leukemia (Hazard Ratio = 1.99; P <.001), presence of anemia (Hazard Ratio =0.09; P =.005), platelets (Hazard Ratio = 2.11; P =.007), hemoglobin (Hazard Ratio = 0.02; P <.001), lymphocytes (Hazard Ratio = 0.29; P =.006), red blood cell (Hazard Ratio = 0.02; P <.001), which patients with Chronic Lymphocytic Leukemia had a significant relationship with time to death. Conclusions: Age, sex, Chronic Lymphocytic Leukemia stage, anemia, platelets, hemoglobin, lymphocytes, and red blood cells were all statistically significant determinants in the time to death of Chronic Lymphocytic Leukemia patients, according to the data. As a result, healthcare providers should pay particular attention to and emphasize the identified characteristics, as well as provide frequent counseling on how to enhance the health of Chronic Lymphocytic Leukemia patients. [ABSTRACT FROM AUTHOR] |
